The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.
NCT ID: NCT05043311
Last Updated: 2022-01-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE1/PHASE2
Total Enrollment
300 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-12-22
Study Completion Date
2023-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
NCT05043285
COVID-19
SARS-CoV-2 Infection
UNKNOWN
PHASE1/PHASE2
The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
NCT05148091
COVID-19
COMPLETED
PHASE1/PHASE2
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
NCT05238454
COVID-19
SARS-CoV-2 Infection
UNKNOWN
PHASE2
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
NCT05238441
COVID-19
Sars-CoV-2 Infection
UNKNOWN
PHASE2
A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years
NCT05308576
COVID-19
SARS-CoV-2 Infection
ACTIVE_NOT_RECRUITING
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a Phase I/II/III, multicenter, randomized, double-blinded trial designed to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
COVID-19
SARS-CoV-2 Infection
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
This is a randomized, double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety, tolerability and immunogenicity of SCTV01C (A Bivalent Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Variants) in healthy population aged ≥18 years previously vaccinated with mRNA vaccine against COVID-19.
In the study, participants receive 20 µg dose or placebo, 40 µg dose or placebo.
In the study, participants receive 20 µg dose or placebo, 40 µg dose or placebo.
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental: 20 µg dose, 18-59 years of age (phase 1/2)
Group Type
EXPERIMENTAL
SCTV01C
Intervention Type
BIOLOGICAL
intramuscular injection
Experimental: 20 µg dose, ≥60 years of age (phase 1/2)
Group Type
EXPERIMENTAL
SCTV01C
Intervention Type
BIOLOGICAL
intramuscular injection
Experimental: 40 µg dose, 18-59 years of age (phase 1/2)
Group Type
EXPERIMENTAL
SCTV01C
Intervention Type
BIOLOGICAL
intramuscular injection
Experimental: 40 µg dose, ≥60 years of age (phase 1/2)
Group Type
EXPERIMENTAL
SCTV01C
Intervention Type
BIOLOGICAL
intramuscular injection
Placebo Comparator: Placebo, 18-59 years of age (phase 1/2)
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
intramuscular injetion
Placebo Comparator: Placebo, ≥60 years of age (phase 1/2)
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
intramuscular injetion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SCTV01C
intramuscular injection
Intervention Type
BIOLOGICAL
Placebo
intramuscular injetion
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Phase I:
Participants are eligible to be included in the study only if the following conditions are met:
1. Male or female aged ≥18 years old when signing ICF;
2. Participants that were fully vaccinated with mRNA anti-SARS-CoV-2 vaccine, and the last dose is ≥6 months away from the vaccination of this study.
3. Participants that can sign written ICF and voluntarily participate in the trial, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial;
4. Ability to read, understand, and fill in record cards;
5. Those who are clinically judged to be healthy, the results of physical examination, vital signs and laboratory tests during the screening period are normal, or although beyond the normal reference range, they are judged by investigators to be of no clinical significance;
6. Fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after the study vaccination; the pregnancy test results of women of childbearing age are negative on screening.
Phase II:
Participants are eligible to be included in the study only if the following conditions are met:
1. Male or female aged ≥18 years old when signing ICF;
2. Participants that were fully vaccinated with mRNA anti-SARS-CoV-2 vaccine, and the last dose is ≥6 months away from the vaccination of this study.
3. Participants that can sign written ICF and voluntarily participate in the trial, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial;
4. Ability to read, understand, and fill in record cards;
5. Healthy participants or participants with pre-existing medical conditions who are in stable condition. The "pre-existing medical conditions" include but not limited to hypertension, diabetes, Chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. A stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment;
6. Fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after the study vaccination; the pregnancy test results of women of childbearing age are negative on screening.
Participants are eligible to be included in the study only if the following conditions are met:
1. Male or female aged ≥18 years old when signing ICF;
2. Participants that were fully vaccinated with mRNA anti-SARS-CoV-2 vaccine, and the last dose is ≥6 months away from the vaccination of this study.
3. Participants that can sign written ICF and voluntarily participate in the trial, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial;
4. Ability to read, understand, and fill in record cards;
5. Those who are clinically judged to be healthy, the results of physical examination, vital signs and laboratory tests during the screening period are normal, or although beyond the normal reference range, they are judged by investigators to be of no clinical significance;
6. Fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after the study vaccination; the pregnancy test results of women of childbearing age are negative on screening.
Phase II:
Participants are eligible to be included in the study only if the following conditions are met:
1. Male or female aged ≥18 years old when signing ICF;
2. Participants that were fully vaccinated with mRNA anti-SARS-CoV-2 vaccine, and the last dose is ≥6 months away from the vaccination of this study.
3. Participants that can sign written ICF and voluntarily participate in the trial, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial;
4. Ability to read, understand, and fill in record cards;
5. Healthy participants or participants with pre-existing medical conditions who are in stable condition. The "pre-existing medical conditions" include but not limited to hypertension, diabetes, Chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. A stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment;
6. Fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after the study vaccination; the pregnancy test results of women of childbearing age are negative on screening.
Exclusion Criteria
Phase I:
A participant who conforms to any of the following criteria should not be enrolled in the study:
1. Previous diagnosis of COVID-19;
2. High-risk populations (such as medical workers, close contacts of patients with COVID-19 infection, etc.) who are more likely to be infected with SARS-Cov-2;
3. Presence of fever within 3 days before the study vaccination;
4. A history of infection or disease related to severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or corresponding immunosuppressants;
5. A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
6. A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
7. Immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including Guillain-Barre Syndrome \[GBS\], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc.;
8. Long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment, or plan to use immunosuppressant therapy or immunomodulatory drugs within two years after enrollment. Whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed.
9. Patients on antituberculosis therapy;
10. Previously or currently suffering from clinically significant cardiovascular diseases, or clinically significant disorders related to respiratory system, liver and kidney, gastrointestinal system, endocrine system, blood and lymphatic system, metabolic and skeletal systems, or malignancies, that may affect the study assessment, or cause risks during the study vaccination, or interfere with the data interpretation as determined by the investigator;
11. Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
12. Participants who received any immunoglobulin or blood products in the previous 3 months, or plan to receive similar products during the study;
13. Participants who received other investigational drugs within 1 month before the study vaccination;
14. Participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis;
15. Participants received other drug used for prevention of COVID-19 (exception for previous mRNA vaccine the participant received) ;
16. Participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination;
17. Those who donated blood or had blood loss (≥450 mL) within 3 months before the vaccination or plan to donate blood during the study period;
18. Those who are pregnant or breast-feeding;
19. Those who plan to donate ovum or sperms during the study period;
20. Those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
21. Those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;
22. Those who are tested positive for hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis or HIV in terms of serology.
Phase II:
A participant who conforms to any of the following criteria should not be enrolled in the study:
1. Previous diagnosis of COVID-19;
2. Presence of fever within 3 days before the study vaccination;
3. A history of infection or disease related to severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or corresponding immunosuppressants;
4. A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
5. A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
6. Immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including Guillain-Barre Syndrome \[GBS\], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc.;
7. Long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment, or plan to use immunosuppressant therapy or immunomodulatory drugs within two years after enrollment. Whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed.
8. Patients on antituberculosis therapy;
9. Presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (except for skin basal cell carcinoma and carcinoma in-situ of cervix) , such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia;
10. Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
11. Participants who received any immunoglobulin or blood products in the previous 3 months, or plan to receive similar products during the study;
12. Participants who received other investigational drugs within 1 month before the study vaccination;
13. Participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis;
14. Participants received other drug used for prevention of COVID-19 (exception for previous mRNA vaccine the participant received) ;
15. Participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination;
16. Those who donated blood or had blood loss (≥450 mL) within 3 months before the vaccination or plan to donate blood during the study period;
17. Those who are pregnant or breast-feeding;
18. Those who plan to donate ovum or sperms during the study period;
19. Those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
20. Those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;
21. Those who are tested positive for HIV in terms of serology.
A participant who conforms to any of the following criteria should not be enrolled in the study:
1. Previous diagnosis of COVID-19;
2. High-risk populations (such as medical workers, close contacts of patients with COVID-19 infection, etc.) who are more likely to be infected with SARS-Cov-2;
3. Presence of fever within 3 days before the study vaccination;
4. A history of infection or disease related to severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or corresponding immunosuppressants;
5. A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
6. A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
7. Immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including Guillain-Barre Syndrome \[GBS\], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc.;
8. Long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment, or plan to use immunosuppressant therapy or immunomodulatory drugs within two years after enrollment. Whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed.
9. Patients on antituberculosis therapy;
10. Previously or currently suffering from clinically significant cardiovascular diseases, or clinically significant disorders related to respiratory system, liver and kidney, gastrointestinal system, endocrine system, blood and lymphatic system, metabolic and skeletal systems, or malignancies, that may affect the study assessment, or cause risks during the study vaccination, or interfere with the data interpretation as determined by the investigator;
11. Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
12. Participants who received any immunoglobulin or blood products in the previous 3 months, or plan to receive similar products during the study;
13. Participants who received other investigational drugs within 1 month before the study vaccination;
14. Participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis;
15. Participants received other drug used for prevention of COVID-19 (exception for previous mRNA vaccine the participant received) ;
16. Participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination;
17. Those who donated blood or had blood loss (≥450 mL) within 3 months before the vaccination or plan to donate blood during the study period;
18. Those who are pregnant or breast-feeding;
19. Those who plan to donate ovum or sperms during the study period;
20. Those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
21. Those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;
22. Those who are tested positive for hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis or HIV in terms of serology.
Phase II:
A participant who conforms to any of the following criteria should not be enrolled in the study:
1. Previous diagnosis of COVID-19;
2. Presence of fever within 3 days before the study vaccination;
3. A history of infection or disease related to severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or corresponding immunosuppressants;
4. A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
5. A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
6. Immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including Guillain-Barre Syndrome \[GBS\], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc.;
7. Long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment, or plan to use immunosuppressant therapy or immunomodulatory drugs within two years after enrollment. Whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed.
8. Patients on antituberculosis therapy;
9. Presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (except for skin basal cell carcinoma and carcinoma in-situ of cervix) , such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia;
10. Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
11. Participants who received any immunoglobulin or blood products in the previous 3 months, or plan to receive similar products during the study;
12. Participants who received other investigational drugs within 1 month before the study vaccination;
13. Participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis;
14. Participants received other drug used for prevention of COVID-19 (exception for previous mRNA vaccine the participant received) ;
15. Participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination;
16. Those who donated blood or had blood loss (≥450 mL) within 3 months before the vaccination or plan to donate blood during the study period;
17. Those who are pregnant or breast-feeding;
18. Those who plan to donate ovum or sperms during the study period;
19. Those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
20. Those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;
21. Those who are tested positive for HIV in terms of serology.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sinocelltech Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yang Wang, Ph.D.
Role: STUDY_DIRECTOR
Sinocelltech Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al Kuwait Hospital (Al Baraha Hospital)
Dubai, , United Arab Emirates
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United Arab Emirates
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
+971 4 271 0000
References
Explore related publications, articles, or registry entries linked to this study.
Hannawi S, Saifeldin L, Abuquta A, Alamadi A, Mahmoud SA, Hassan A, Liu D, Yan L, Xie L. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial. EBioMedicine. 2023 Jan;87:104386. doi: 10.1016/j.ebiom.2022.104386. Epub 2022 Dec 5.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCTV01C-01-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
NCT04352608
COMPLETED
PHASE1/PHASE2
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
NCT05522829
UNKNOWN
PHASE2
A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
NCT05903118
COMPLETED
PHASE1/PHASE2
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
NCT05652543
COMPLETED
PHASE2
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
NCT05329051
UNKNOWN
PHASE2
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
NCT05308602
WITHDRAWN
PHASE2
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
NCT05323461
UNKNOWN
PHASE3
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
NCT05239806
UNKNOWN
PHASE2
A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study
NCT05038618
COMPLETED
PHASE2
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study
NCT05048849
COMPLETED
PHASE2
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
NCT05439824
UNKNOWN
PHASE2
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine
NCT06754605
RECRUITING
PHASE1/PHASE2
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
NCT05345873
UNKNOWN
PHASE2
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
NCT05354089
UNKNOWN
PHASE1
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
NCT05144139
COMPLETED
PHASE1/PHASE2
Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
NCT05373485
COMPLETED
PHASE1
An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older
NCT05679466
UNKNOWN
EARLY_PHASE1
Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
NCT05373472
COMPLETED
PHASE2
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
NCT04649021
COMPLETED
PHASE2
A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
NCT06113744
RECRUITING
PHASE1
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
NCT05664932
UNKNOWN
PHASE3
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
NCT05995275
COMPLETED
PHASE1/PHASE2
A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
NCT06113731
RECRUITING
PHASE2
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine
NCT04545749
COMPLETED
PHASE1